Global Anti-Epileptic Drugs Market: Overview
The anti-epileptic drugs are those medications that are developed for the purpose of idiopathic and asymptomatic treatment of seizures and epilepsy. In addition to epilepsy and seizures, antiepileptic drugs can also be taken for the purpose of treatment of neuropathic pain. Exact causes of epileptic seizures are still not defined or determined. However, the main factors that contribute towards epilepsy comprise incidents such as substance use disorders, stroke, and brain injury. Antiepileptic drugs or medicines (AEDs), treatment of epilepsy are prescribed based on the age of the patient, part of the brain that is affected, and type of seizures to be treated. In addition to that, expanding base of geriatric population, dietary habits, intake of alcohol, and smoking are some of the significant factors that are triggering growth of the global anti-epileptic drugs market. Anti-epileptic drugs are also known as anti-seizure drugs in the market.
View Report: https://www.transparencymarketresearch.com/anti-epileptic-drugs-market.html
In its new report on global anti-epileptic drugs market, Transparency Market Research has shed light on all the aspects of global Anti-Epileptic Drugs. Market drivers, restraints, opportunities, trends, key players, and forecasts have been discussed into detail. The information that has been shared is sure to offer success mantra for the businesses that are operating the market.
Global Anti-Epileptic Drugs Market: Notable Developments
Key players that are operating in the global anti-epileptic drugs market are constantly trying for mergers and acquisitions to expand their regional footprint. Many new innovative ideas are coming up to keep the businesses afloat in the forthcoming years and stay competitive in the market.
- Pfizer Inc. has made announcement of the successful completion of its acquisition process of Therachon Holding AG., a privately held clinical-stage biotechnology company. Under the prevailing terms of the said transaction, Therachon Holding AG was acquired by Pfizer Inc. an additional USD 470 million, over and above $340 million. The additional payment of USD 470 million was made following the achievement of key milestones in the commercialization and development of TA-46.
Valeant Pharmaceuticals International, Abbott Laboratories, Johnson & Johnson, GlaxoSmithKline plc and Sunovion Pharmaceuticals are a few of the noted players operating in in the global anti-epileptic drugs market.
Global Anti-Epileptic Drugs Market: Key Trends
The global anti-epileptic drugs market is projected to exhibit the following market trends and opportunities:
Valporic Acid to Lead Market Growth due to Increased Usage
Of all the anti-epileptic drugs, the valporic acid is expected to account for most of the share in the market over the forecast timeframe owing to its effective usage and drug structure. Valporic acids find its usage in most types of seizures. However, the fastest growth rate is forecasted to be displayed by Lacosamide drug over the period of forecast due to a surge in its adoption by the patients and healthcare professionals in the anti-epileptic drugs market alike. Such increased adoption is owing to its homogenous structure. In addition to that, availability of technologically advanced treatment and medically advanced diagnosis prescribing usage of anti-epileptic drugs are likely to shoot up the demand for the market. Growing demand for home-based anti-epileptic drugs treatment are likely to propel the growth of global anti-epileptic drugs market in the forthcoming years.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=69882
Global Anti-Epileptic Drugs Market: Geographical Analysis
In terms of geography, global anti-epileptic drugs market is segregated into the regions of North America, Europe, Asia-Pacific and Latin America, Middle East and Africa (LAMEA). Europe and North America command the global anti-epileptic drugs market owing to extensive research & development activities. Presence of approved second-generation anti-epileptics drugs is forecasted to trigger market growth. Apart from these two regions, Asia-pacific is estimated to be fastest growing market because of better penetration of antiepileptic drugs and high prevalence of epilepsy.